Revisiting Interventions in Aseptic Processing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Revisiting Interventions in Aseptic Processing
The authors revisit their previous effort to refine the terms that describe interventions and to dispel confusion that arose after the original article was published.


Pharmaceutical Technology
Volume 35, Issue 4, pp. 69-72

Sterility by design

The authors's article titled "The Myth Called 'Sterility'" reviewed the current controls for aseptic processing (4). In that article, the authors stated that the existing controls for assessing aseptic processing performance are largely inadequate to ensure the sterility of the materials being produced. Although industry might not understand it fully, reliance on sampling and monitoring is no longer adequate. In fact, some unscientific compliance approaches imply that sterility can be monitored, validated, or tested into a process.

The capabilities of modern aseptic processing exceed the ability of the current measurement tools. The authors previously outlined the components of aseptic operations that should be considered to attain sterility. The description of these components focused on design considerations that minimized or eliminated the need for operator intervention. The concepts embodied in that article are perhaps most directly applicable to the design of new aseptic processing facilities, or to equipment or component selection. Nevertheless, the article includes the following recommendations that can be applied without significant capital investment:

  • Glass and plastic containers, elastomeric closures, and other primary package components with tight acceptable quality levels can reduce the need for interventions.
  • Robustly controlled and validated preparation and siliconization procedures that are consistent can reduce handling difficulties and the interventions needed to remediate them.
  • Applying the suggestions about intervention management can help reduce the impact of interventions.

Sterility—or, more accurately, microbiological safety suitable for injectable medicines—is accomplished through design more than any other means. Excessive tolerance of interventions, whether inherent or corrective, amounts to settling for an inferior design. Given the negative outcomes that can result from interventions, the goal must be to minimize them. Facility, equipment, and procedures must be designed, specified, and defined with that intent.

Conclusion

The authors' vision of the future is one in which advanced aseptic processing is universal and direct human interaction with sterile materials never occurs (5–8). Until these systems are universal, the need for aseptic interventions will persist, and firms should organize their interventional activities to mitigate the risk of contamination. The authors maintain that interventions should be avoided at all times. It is instructive to remember Hank Avallone's important lesson: "It is useful to assume that the operator is always contaminated while operating in the aseptic area. If the procedures are viewed from this perspective, those practices which are exposing the product to contamination are more easily identified" (9).

James Agalloco* is president of Agalloco & Associates, PO Box 899, Belle Mead, NJ 08502, tel. 908.874.7558,
. He also is a member of Pharmaceutical Technology's editorial advisory board. James Akers is president of Akers Kennedy & Associates.

*To whom all correspondence should be addressed.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here